Conclusions: Abnormal repertoires and impaired isotype expression are seen in patients with common variable immunodeficiency, these data suggested that rituximab after APBSCT can affect not only the B-cell quantities, but also the recovery of the B-cell repertoires.
Introduction
High dose chemotherapy followed by autologous peripheral blood stem cell transplantation (APBSCT) has been widely used for patients with non-Hodgkin's lymphoma (NHL) (1) (2) (3) . Although APBSCT for patients with high risk aggressive lymphoma may give a prolonged disease free survival (4), relapse is still the primary cause of failure after APBSCT. In addition to residual disease after APBSCT, the reinfusion of tumor cells in the autologous graft may contribute to a relapse.
Rituximab, a chimeric anti-CD20 monoclonal antibody, has a good safety profile and, hence, it has been incorporated into many chemotherapeutic regimens and in vivo purging before autologous graft harvest (5, 6) . It has been also used as one of the most effective approaches for adjuvant therapy after APBSCT to eradicate the minimal residual disease that leads to relapse (7) (8) (9) .
Rituximab alone does not appear to cause severe hypogammaglobulinemia according to initial phase I and II clinical trials (10) . However, recent studies revealed that patients who received rituximab as an adjuvant to APBSCT had an increased risk of developing severe hypogammaglobulinemia (7, 8, 11) . In addition, prolonged hypogammaglobulinemia with rituximab has also been seen in patients with post transplant Epstein-Barr virus associated lymphoproliferative disorder (EBLPD) (12) (13) (14) (15) or human immunodeficiency virus (HIV) associated lymphoma (16) .
The mechanism of this hypogammglobulinemia is unknown, although investigators have hypothesized a delay in the B-cell recovery as one potential etiology.
We previously reported severe persistent panhypogammglobulinemia after rituximab therapy for post transplant Epstein-Barr virus associated autoimmune hemolytic anemia in a Japanese woman (17) . We found her B cells to be composed of only CD27 negative naive B cells. In addition, her peripheral blood mononuclear cells (PBMC) only expressed transcriptions of IgM, IgG1, IgA1 and IgA2 but no IgG2, IgG3 and IgG4. These impaired B-cell repertoires, which are also seen in patients with common variable immunodeficiency (CVID) (18) , were speculated to cause her hypogammaglobulinemia. We hypothesized that the same abnormal patterns could be found in the NHL patients treated with APBSCT plus rituximab and therefore performed phenotypical and genetic studies to test our hypothesis.
Patients, materials and methods

Patients and Treatment
From August 2001 to August 2004, a total of 17 Japanese patients with newly diagnosed B-cell NHL were enrolled in our protocol which included APBSCT (5, 19) .
The eligibility criteria for APBSCT were as follows: age between 15 and 65 years; a confirmed histologic diagnosis of CD20-positive B-cell NHL (excluding Burkitt's lymphoma and lymphoblastic lymphoma); prognostic index, constructed by Coiffier et al (20) , of intermediate or high risk as defined by having at least one of the four following adverse features: (1) elevated serum lactic dehydrogenase (LDH) level, (2) bulky mass >10 cm, (3) advanced stage III or IV according to Ann Arbor staging classification, (4) two or more extranodal sites: no severe cardiopulmonary, renal and hepatic dysfunction. After APBSCT, six patients, two who died of NHL and four who were seen by the local physicians, dropped out during the follow-up. Besides these eleven patients, three patients (UPN4, 9 and 13) were enrolled during their first relapse after three to six cycles of CHOP. As a result, a total of fourteen patients were evaluated in this study.
All newly diagnosed patients were initially treated with three cycles of CHOP (21) every two weeks with G-CSF (Lenograstim, Chugai Pharmaceutical CO., Tokyo, Japan) support as induction chemotherapy. One or two leukaphresis were performed after a fourth cycle of CHOP therapy (5). After November 2001, when rituximab was available in Japan, PBSC were mobilized using CHOP plus rituximab (Chugai Pharmaceutical CO., Tokyo, Japan) intended as in vivo purging (5) . After the fourth cycle of CHOP, the patients' responses to the initial CHOP were evaluated.
While those who achieved tumor reduction rates of more than 50% were treated with two additional cycles of CHOP, those showing less then a 50% response were considered to be resistant to CHOP and thus were treated with other salvage regimens, including two cycles of DHAP (dexamethasone, cytarabine and cisplatin) (22) or FMD (fludarabine, mitxantrone and dexamethasone) regimens (23) . Pretransplant conditioning regimens for all patients consisted of ranimustine, carboplatin, etoposide and cyclophosphamide (MCVC regimen) (19) .
After engraftment, rituximab at a dose of 375 mg/m 2 was given weekly for up to four weeks. All patients achieved complete remission after APBSCT. The approval to perform these studies was obtained from the Hokkaido University Hospital's and the Sapporo City General Hospital's institutional review board. Informed consent was provided according to the Declaration of Helsinki protocol.
Cell Preparation
After obtaining the patients' informed consent, blood samples were collected from the patients at the Hokkaido University Hospital with the approval of the ethics committee of Hokkaido University. Peripheral blood mononuclear cells (PBMC)
were isolated via density-gradient centrifugation with Ficoll-Hypaque (Pharmacia, Uppsala, Sweden). Normal PBMC were obtained from the buffy-coat of blood samples collected from adult volunteers at the Hokkaido Blood Bank.
Flow Cytometry
Three-color flow cytometric immunophenotyping was performed to determine the proportion of lymphocyte subsets. 
RT-PCR of immunoglobulin transcripts
Total RNA was isolated from PBMC (5 x 10 6 cells), using the RNeasy Mini Kit (QIAGEN, Valencia, CA). Subsequently, first-strand cDNA synthesis was performed with SuperScript TM First-Strand Synthesis System for RT-PCR (Invitrogen, Carlsbad, CA), according to the manufacturer's instructions. The primers of the different human immunoglobulin isotypes were used as described previously (18) .
PCR amplification was performed with reverse-transcribed material and 0.5 U AmpliTaq Gold plymerase (Takara, Japan) with an initial step of 5 min at 95°C; then 40 cycles each consisting of 1 min of extension at 72°C; and at least a final extension for 10 min at 72°C. The reaction products were electrophoresed on 2% agarose gel.
Statistical Analysis
For statistical comparisons between the groups, the Mann-Whiteny U-test was used. Analyses were performed using Glanzman's "Primer of Biostatistics" software package (McGraw-Hill Inc., New York, NY).
Results
Incidence of hypogammaglobulinemia after APBSCT and rituximab
After a median follow-up of 33.5 months (range 12 to 43 months), we found six patients who had hypogammaglobulinemia (Group A), as defined by the serum IgG levels of less than 8.0 g/l (normal range 8.7 to 17.0 g/l), while the other eight patients (Group B) had normal serum IgG levels. There were three follicular lymphoma (FL), two diffuse large cell lymphoma (DLCL) and one mantle cell lymphoma in Group A, and three FL and five DLCL in Group B. The backgrounds of the two groups were not different, including age, the number of CD34 positive cells transplanted, the follow-up period or the dose of rituximab pre-or post-APBSCT (Table 1) . We also found the IgA levels to be significantly lower in Group A than 
Impaired isotype expression in patients who have hypogammaglobulinemia
The phenotypical analysis suggested that Group A patients had similar abnormal patterns to those with CVID. As a result, we evaluated immunoglobulin isotype production by analyzing the immunoglobulin transcripts by RT-PCR, as patients with CVID are also known to have impaired immunoglobulin class switching (18, 24) . Although control donors always expressed each isotype (data not shown),
we observed that all patients tested in Group A had defected one or more isotype mRNA transcript expressions in IgG (Table 3) . On the other hand, all patients in Group B, except for UPN12 who lacked only IgG4 transcript, showed the normal IgG transcript with RT-PCR. While the IgM mRNA transcript was seen in PBMC of all patients, the transcript of IgA2 was absent in six out of thirteen tested patients and there appeared to be no differences between the two groups. Taken together with the phenotypical analysis, these data indicate that Group A patients had not only a small number of B-cells, but also abnormal repertories in B-cells.
Bone marrow examinations after APBSCT and rituximab
Bone marrow examinations were performed in nine patients to evaluate any evidence of a relapse. A total 500 cells were evaluated microscopically, and the plasma cells were recognized by their unique morphology. While we found plasma cells (normal range 0.8-1.6%) in all five specimens tested in the Group B patients, only one out of four from Group A specimens showed the existence of plasma cells in the bone marrow. (Table 4 )
Clinical complications with hypogammaglobulinemia
UPN1 developed repeated bacterial infections and required the intravenous administrations of immunoglobulin (IVIG). However, the other five patients in Group
A, as well as all patients in Group B, have been asymptomatic and required no IVIG.
Discussion
Increasingly, attention is being focused on immune-based therapy for the treatment of NHL. Rituximab is the one of the most frequently administered and well-established monoclonal antibodies which specifically targets CD20 antigen on malignant B cells. CD20 is also expressed on normal B cells, but not on plasma cells, and that has been believed to be the reason why this monoclonal antibody would not cause hypogammaglobulinemia when it was administered as a single agent in earlier studies. However, our survey revealed that six out of fourteen patients (43%) developed hypogammaglboulinemia which was much higher than expected in light of its safety profile when it is used as a single agent. Table 2 ).
In addition, the defects of some isotype transcripts in PBMC, which have also been found in patients with CVID, were dominantly seen in Group A (Table 3) . But this defect of isotype expression was not specific for Group A, as some patients in The reported cases with rituximab related hypogammaglobulinemia were mostly seen in patients who were put under the additional cellular immunosuppression, namely stem cell transplantations (7, 8, 26) , organ transplantations (12) (13) (14) or HIV infection (16) . Moreover, the maintenance rituximab (Table 4) . However, more cases are required to confirm an absence of plasma cells to determine the precise pathogenesis of this hypogammglobulinemia.
In conclusion, our results suggest that rituximab administration after APBSCT 
